Clinical Trials
20 trialsNCT03992456 2024-05-21
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Unknown
NCT05962450 2024-01-16
Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy
Beijing YouAn Hospital
Phase 2 Unknown
NCT05370807 2023-10-24
RegoMel
Universitair Ziekenhuis Brussel
Phase 2 Unknown
NCT06089330 2023-10-18
A Study of JMT101 in Patients With Metastatic Colorectal Cancer
Shanghai JMT-Bio Inc.
Phase 2 Unknown
NCT02365441 2023-07-07
ALT GIST
Australasian Gastro-Intestinal Trials Group
Phase 2 Unknown
NCT05382741 2023-05-17
VIVA
Ospedale Policlinico San Martino
Phase 2 Unknown
NCT05134532 2023-04-26
HCC
CHA University
Phase 2 Unknown
NCT05048017 2023-03-29
Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT02619435 2023-03-24
STREAM
National Cancer Institute, Naples
Phase 2 Unknown
NCT04030260 2023-03-23
Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT04718909 2022-11-10
REGSIN
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown
NCT05535647 2022-09-10
Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05524155 2022-09-01
Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05485909 2022-08-03
Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM
Sun Yat-sen University
Phase 2 Unknown
NCT05130021 2021-12-06
A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer
Maxinovel Pty., Ltd.
Phase 2 Unknown
NCT02501551 2021-04-05
Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy
Yonsei University
Phase 2 Unknown
NCT02162914 2020-07-31
REACHIN
Erasme University Hospital
Phase 2 Unknown
NCT03880877 2019-03-21
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 2 Unknown
NCT01949194 2018-08-10
Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers
Jewish General Hospital
Phase 2 Unknown
NCT02288078 2014-11-13
Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402)
Clinical Research Support Center Kyush
Phase 2 Unknown